Advertisement

PCSK9 in HIV infection: New opportunity or red herring?

  • Massimiliano Ruscica
    Correspondence
    Corresponding author. Department of Pharmacological and Biomolecular Sciences, Via Balzaretti 9, 20133, Milano, Italy. Tel.: 00390250318220; fax: 00390250318297.
    Affiliations
    Department of Pharmacological and Biomolecular Sciences, Università Degli Studi di Milano, Milan, Italy
    Search for articles by this author
  • Gerald F. Watts
    Affiliations
    School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Australia
    Lipid Disorders Clinic, Cardiometabolic Services, Department of Cardiology, Royal Perth Hospital, Perth, Australia
    Familial Hypercholesterolaemia Australia Network, Australia
    Search for articles by this author
  • Cesare R. Sirtori
    Affiliations
    Centro Dislipidemie, A.S.S.T. Grande Ospedale Metropolitano Niguarda, Milan, Italy
    Search for articles by this author
      While modern drug therapy has improved survival of patients with immune deficiency virus (HIV) infection, the rate of myocardial infarction among affected individuals has increased by 50% [
      • Freiberg M.S.
      • Chang C.C.
      • Kuller L.H.
      • et al.
      HIV infection and the risk of acute myocardial infarction.
      ]. This is not explicable by conventional cardiovascular (CV) risk factors and could relate to HIV infection itself or to specific drug treatments [
      • Hsue P.Y.
      • Waters D.D.
      Time to recognize HIV infection as a major cardiovascular risk factor.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Freiberg M.S.
        • Chang C.C.
        • Kuller L.H.
        • et al.
        HIV infection and the risk of acute myocardial infarction.
        JAMA Intern. Med. 2013; 173: 614-622
        • Hsue P.Y.
        • Waters D.D.
        Time to recognize HIV infection as a major cardiovascular risk factor.
        Circulation. 2018; 138: 1113-1115
        • Gencer B.
        • Pagano S.
        • Vuilleumier N.
        • et al.
        Clinical, behavioral and biomarker predictors of pcsk9 levels in hiv-infected patients naïve of statin therapy: a cross-sectional analysis from the swiss hiv cohort.
        Atherosclerosis. 2019; : 253-259
        • Raposeiras-Roubin S.
        • Abu-Assi E.
        • Iniguez-Romo A.
        Tobacco, illicit drugs use and risk of cardiovascular disease in patients living with HIV.
        Curr. Opin. HIV AIDS. 2017; 12: 523-527
        • Feinstein M.J.
        • Nance R.M.
        • Drozd D.R.
        • et al.
        Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the centers for AIDS research network of integrated clinical systems.
        JAMA Cardiol. 2017; 2: 155-162
        • Burkholder G.A.
        • Muntner P.
        • Zhao H.
        • et al.
        Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus.
        J. Clin Lipidol. 2018; 12: 988-998 e985
        • Stein J.H.
        • Hsue P.Y.
        Inflammation, immune activation, and CVD risk in individuals with HIV infection.
        J. Am. Med. Assoc. 2012; 308: 405-406
        • Triant V.A.
        • Meigs J.B.
        • Grinspoon S.K.
        Association of C-reactive protein and HIV infection with acute myocardial infarction.
        J. Acquir. Immune Defic. Syndr. 2009; 51: 268-273
        • Ruscica M.
        • Ferri N.
        • Corsini A.
        • et al.
        PCSK9 antagonists and inflammation.
        Atherosclerosis. 2018; 268: 235-236
        • Hsue P.Y.
        • Li D.
        • Ma Y.
        • et al.
        IL-1beta inhibition reduces atherosclerotic inflammation in HIV infection.
        J. Am. Coll. Cardiol. 2018; 72: 2809-2811
        • Subramanian S.
        • Tawakol A.
        • Burdo T.H.
        • et al.
        Arterial inflammation in patients with HIV.
        J. Am. Med. Assoc. 2012; 308: 379-386
        • Tsimikas S.
        A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies.
        J. Am. Coll. Cardiol. 2017; 69: 692-711
        • Enkhmaa B.
        • Anuurad E.
        • Zhang W.
        • et al.
        Effect of antiretroviral therapy on allele-associated Lp(a) level in women with HIV in the Women's Interagency HIV Study.
        J. Lipid Res. 2018; 59: 1967-1976
        • Macchi C.
        • Banach M.
        • Corsini A.
        • et al.
        Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
        Eur. J. Prev. Cardiol. 2019; (2047487319831500)
        • Kohli P.
        • Ganz P.
        • Ma Y.
        • et al.
        HIV and hepatitis C-coinfected patients have lower low-density lipoprotein cholesterol despite higher proprotein convertase subtilisin kexin 9 (PCSK9): an apparent "PCSK9-lipid paradox.
        J. Am. Heart Assoc. 2016; 5
        • Guaraldi G.
        • Raggi P.
        Antiretroviral therapies and cardiovascular risk: true or false?.
        Atherosclerosis. 2017; 263: 313-314
        • Maggi P.
        • Bellacosa C.
        • Leone A.
        • et al.
        Cardiovascular risk in advanced naive HIV-infected patients starting antiretroviral therapy: comparison of three different regimens - PREVALEAT II cohort.
        Atherosclerosis. 2017; 263: 398-404
        • Ravi D.
        • Ghasemiesfe M.
        • Korenstein D.
        • et al.
        Associations between marijuana use and cardiovascular risk factors and outcomes: a systematic review.
        Ann. Intern. Med. 2018; 168: 187-194
        • Lorenz D.R.
        • Dutta A.
        • Mukerji S.S.
        • et al.
        Marijuana use impacts midlife cardiovascular Events in HIV-infected men.
        Clin. Infect. Dis. 2017; 65: 626-635
        • Steffens S.
        • Veillard N.R.
        • Arnaud C.
        • et al.
        Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
        Nature. 2005; 434: 782-786
        • Ward N.C.
        • Page M.M.
        • Watts G.F.
        PCSK9 inhibition 2018: riding a new wave of coronary prevention.
        Clin. Sci. (Lond.). 2019; 133: 205-224
        • Arrive E.
        • Viard J.P.
        • Salanave B.
        • et al.
        Metabolic risk factors in young adults infected with HIV since childhood compared with the general population.
        PLoS One. 2018; 13e0206745
        • Angelovich T.A.
        • Hearps A.C.
        • Oda M.N.
        • et al.
        Dysfunctional high-density lipoprotein from HIV+ individuals promotes monocyte-derived foam cell formation in vitro.
        AIDS. 2017; 31: 2331-2336
        • Dube M.P.
        • Komarow L.
        • Fichtenbaum C.J.
        • et al.
        Extended-release niacin versus fenofibrate in HIV-infected participants with low high-density lipoprotein cholesterol: effects on endothelial function, lipoproteins, and inflammation.
        Clin. Infect. Dis. 2015; 61: 840-849
        • Attridge R.L.
        • Linn W.D.
        • Ryan L.
        • et al.
        Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity.
        J. Clin Lipidol. 2012; 6: 19-26
        • Amador-Licona N.
        • Diaz-Murillo T.A.
        • Gabriel-Ortiz G.
        • et al.
        Omega 3 fatty acids supplementation and oxidative stress in HIV-seropositive patients. A Clinical Trial.
        PLoS One. 2016; 11e0151637
        • Bhatt D.L.
        • Steg P.G.
        • Miller M.
        • et al.
        Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.
        N. Engl. J. Med. 2019; 380: 11-22

      Linked Article